Characteristics | Overall survival | Progression-free survival | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Univariate analysis | Multivariate analysis | N | Univariate analysis | Multivariate analysis | |||||||||
HR | 95% CI | P | Adjusted HR | 95% CI | P | HR | 95% CI | P | Adjusted HR | 95% CI | P | |||
Age, years | ||||||||||||||
≥ 63 | 193 | 1.456 | 0.754–2.813 | 0.263 | 1.234 | 0.592–2.570 | 0.575 | 157 | 1.285 | 0.751–2.197 | 0.360 | 1.224 | 0.676–2.216 | 0.504 |
< 63 | 177 | 1 (Ref) | − | − | 1 (Ref) | − | − | 177 | 1 (Ref) | − | − | 1 (Ref) | − | − |
Histologic type | ||||||||||||||
Non-endometrioid | 66 | 2.232 | 1.146–4.348 | 0.018 | 0.887 | 0.379–2.074 | 0.782 | 57 | 1.987 | 1.112–3.551 | 0.020 | 1.080 | 0.478–2.442 | 0.853 |
Endometrioid | 304 | 1 (Ref) | − | − | 1 (Ref) | − | − | 277 | 1 (Ref) | − | − | 1 (Ref) | − | − |
Grade | ||||||||||||||
G3 | 176 | 3.411 | 1.661–7.004 | 0.001 | 2.016 | 0.874–4.650 | 0.100 | 150 | 1.539 | 0.909–2.607 | 0.109 | 0.884 | 0.453–1.724 | 0.717 |
G1,2 | 194 | 1 (Ref) | − | − | 1 (Ref) | − | − | 184 | 1 (Ref) | − | − | 1 (Ref) | − | − |
FIGO stage | ||||||||||||||
III-IV | 89 | 4.703 | 2.474–8.943 | < 0.001 | 3.509 | 1.734–7.101 | < 0.001 | 72 | 3.704 | 2.176–6.307 | < 0.001 | 3.581 | 1.981–6.473 | < 0.001 |
I-II | 278 | 1 (Ref) | − | − | 1 (Ref) | − | − | 259 | 1 (Ref) | − | − | 1 (Ref) | − | − |
LYL1 amplification | ||||||||||||||
Yes | 22 | 3.096 | 1.201–7.982 | 0.019 | 1.581 | 0.541–4.620 | 0.402 | 18 | 2.469 | 1.055–5.780 | 0.037 | 1.652 | 0.633–4.317 | 0.305 |
No | 348 | 1 (Ref) | − | − | 1 (Ref) | − | − | 316 | 1 (Ref) | − | − | 1 (Ref) | − | − |